GLP-1 Weight Loss Results: Realistic Timeline and Expectations
If you decide to start
Compounded semaglutide $169/month · tirzepatide $219/month
One flat price at every prescribed dose. No membership fee. Medication and discreet shipping included if prescribed.
What the clinical trials actually showed
In the STEP 1 trial, semaglutide 2.4mg weekly injection produced a mean weight loss of 14.9% of baseline body weight versus 2.4% for placebo over 68 weeks in 1,961 adults without diabetes. In SURMOUNT-1, injectable tirzepatide produced mean losses of 15.0% at 5mg, 19.5% at 10mg, and 20.9% at 15mg versus 3.1% for placebo over 72 weeks in 2,539 adults without diabetes. These are separate trials — not head-to-head comparisons — and the figures are means, not individual guarantees.
- Semaglutide (STEP 1)
- 2.4 mg once-weekly injection; 68-week trial mean 14.9% body-weight loss vs 2.4% for placebo (1,961 adults without diabetes).
- Tirzepatide (SURMOUNT-1)
- Injected tirzepatide, 72-week trial means: 15.0% (5mg), 19.5% (10mg), and 20.9% (15mg) vs 3.1% for placebo (2,539 adults without diabetes).
- Important caveat
- STEP 1 and SURMOUNT-1 were separate trials, not a head-to-head comparison. Both studied injected formulations with lifestyle support.
Both studies used brand-name injected formulations alongside lifestyle support. The percentages are averages: some participants lost substantially more, some less, and a small number did not respond meaningfully. Individual results depend on starting weight, age, sex, adherence, lifestyle, and biology. Surfbound treatment uses compounded medications — which are not FDA-approved and have not been studied in the same way — so these trial figures are not a prediction of any individual result.
Published results at 3, 6 and 12 months
A large observational study by Rodriguez et al., published in JAMA Internal Medicine (2024), followed 18,386 propensity-matched adults with overweight or obesity — 52% of whom had type 2 diabetes — and reported mean percent body-weight loss at three timepoints. The estimates below are on-treatment averages for the injected Ozempic (semaglutide) and Mounjaro (tirzepatide) formulations labeled for type 2 diabetes.
Published weight-loss results at 3, 6 and 12 months
| Timepoint | Semaglutide (mean % body-weight loss) | Tirzepatide (mean % body-weight loss) |
|---|---|---|
| 3 months | 3.6% | 5.9% |
| 6 months | 5.8% | 10.1% |
| 12 months | 8.3% | 15.3% |
Source: Rodriguez PJ, et al. JAMA Internal Medicine, 2024 — 18,386 propensity-matched adults with overweight or obesity (52% with type 2 diabetes). | Observational, not randomized; using injected Ozempic/Mounjaro formulations labeled for type 2 diabetes. | On-treatment estimates: discontinuation was common, so these averages reflect those who remained on treatment and are not a monthly guarantee.
Primary source: Rodriguez et al., JAMA Internal Medicine 2024 — full article and the PubMed record (PMID: 38976257).
Scope note: this observational study measured adults on injected semaglutide or tirzepatide labeled for type 2 diabetes. It does not measure Surfbound patients, compounded oral products, or semaglutide-tirzepatide combination outcomes.
Early weeks: following your prescribed escalation
The first weeks are an adaptation period on a sub-therapeutic starting dose. These published sources do not establish a reliable first-month weight-loss number, so no specific early figure should be expected — follow the escalation schedule your licensed provider prescribes.
GLP-1 treatment begins at a low dose that is increased gradually over weeks — a process called titration — so the body can adapt and the chance of gastrointestinal side effects is reduced. Because most studies report results only at later timepoints such as 3, 6, and 12 months, the evidence does not support a dependable first-month weight-loss prediction. What people commonly notice early is a change in appetite and less food noise, alongside possible mild side effects as the body adjusts.
- Appetite changes — reduced hunger and earlier fullness may become noticeable within the first weeks
- Food noise reduction — many people describe a quieting of constant thoughts about food
- Possible mild gastrointestinal side effects as your body adapts
- No dramatic visual changes yet — this is normal and expected
- Follow the prescribed titration exactly — increasing the dose faster than prescribed raises side-effect risk without speeding results
The 3, 6 and 12-month timepoints
Weight loss tends to accumulate across months of consistent treatment rather than arriving on a fixed weekly schedule. The study above reported mean on-treatment losses at 3, 6, and 12 months; the table shows those timepoints side by side. Reading the numbers as milestones at those months — rather than as a week-by-week or month-by-month forecast — matches what the published evidence actually measures.
Two features of these estimates matter for expectations. First, they are averages: individual results ranged higher and lower. Second, they are on-treatment estimates — discontinuation was common, so they describe the people who remained on medication, not everyone who started.
Why results slow over time
Weight loss naturally decelerates as body weight falls and calorie needs decline — the same energy deficit that produced earlier loss has a smaller effect at a lower body weight. This deceleration is expected and does not mean the medication has stopped working.
Rather than projecting a maximum by a specific month, it is more accurate to say that loss generally slows as treatment continues. The published 12-month estimate reflects that longer-term, on-treatment picture. If progress stalls or you have questions about your trajectory, a licensed provider can review your response and adjust the plan.
What influences your individual results
- Starting BMI — people with higher starting weights tend to lose more total pounds
- Adherence — consistent weekly dosing without missed doses produces better results
- Dietary choices — the medication reduces appetite, but nutritional quality still matters
- Physical activity — regular movement, even walking, supports metabolic health and body composition
- Sleep and stress — poor sleep and chronic stress can impair weight loss even with medication
- Genetics — some people are simply stronger responders than others, and this is not something you control
The reality check: what the medication cannot do
GLP-1 medications are powerful tools but they are not magic. They do not selectively target belly fat. They cannot overcome a diet of ultra-processed foods. They do not build muscle — that requires resistance training and adequate protein. They do not fix emotional eating patterns — therapy or coaching may be helpful alongside medication.
The people who get the best results treat the medication as one part of a broader approach: nutrition, movement, sleep, and stress management all working together.
Ready to take the next step?
See if GLP-1 treatment is right for youSources
This guide is published by Surfbound Health (Organization). It is educational content, not medical advice, and it does not replace an individual evaluation by a licensed provider.
Sources
- Rodriguez PJ, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine, 2024 (18,386 propensity-matched adults; observational, not randomized; injected Ozempic/Mounjaro formulations labeled for type 2 diabetes; on-treatment mean body-weight loss at 3, 6, and 12 months).
- Rodriguez PJ, et al. — PubMed record (PMID: 38976257).
- STEP 1 — Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021 (semaglutide 2.4 mg weekly injection, 68 weeks, 1,961 adults without diabetes; trial mean 14.9% vs placebo 2.4%).
- SURMOUNT-1 — Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022 (injectable tirzepatide 5/10/15 mg, 72 weeks, 2,539 adults without diabetes; trial means 15.0%/19.5%/20.9% vs placebo 3.1%).
Frequently asked questions
The published sources do not establish a reliable first-month number, so no specific early figure should be expected. The starting dose is low and meant for adaptation, not maximum weight loss. Appetite changes may appear within the first weeks, but meaningful results are measured over months, not weeks.
A large 2024 observational study reported mean on-treatment body-weight loss at 3, 6, and 12 months — semaglutide 3.6%, 5.8%, and 8.3%; tirzepatide 5.9%, 10.1%, and 15.3%. Separately, STEP 1 reported a 14.9% mean at 68 weeks for semaglutide 2.4mg, and SURMOUNT-1 reported 15.0% to 20.9% at 72 weeks for tirzepatide. These are averages from separate studies — not guarantees, and not a monthly forecast.
Weight loss naturally decelerates as body weight falls and calorie needs decline. This is expected and does not mean the medication has stopped working. Your provider may review your response and adjust your plan, or you may need to evaluate your nutrition and activity patterns.
Clinical data shows that most people regain some or all of the lost weight after discontinuing GLP-1 medication. These medications are designed for long-term use. Any decision to discontinue should be made with your provider and include a plan for weight maintenance.
Physical activity supports better body composition outcomes — preserving muscle mass while losing fat — and contributes to overall metabolic health. While exercise alone produces modest weight loss, combining it with GLP-1 treatment tends to produce better overall results than medication alone.
Want more evidence-based health research from Surfbound?
Add Surfbound as a Preferred Source on Google